Fast Plaque Clearance with Little ARIA? So Teases Trontinemab at AD/PD 2024 TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative, Again Therapeutic Contenders Target Hard-to-Reach Pockets of Tau Mouse Models and Markers for Cerebral Amylo
Last summer saw a first: the traditional approval of a disease-modifying Alzheimer's therapy. Solid progress on biomarkers, and a flourishing of basic research, made for a good year.
When LOAD2 mice, which carry Alzheimer’s risk variants, eat a fatty diet, their proteomes change, their neurons die, and their memories fail. All sans amyloid plaques.
ALZpath’s assay detected an annual rise in plasma phospho-tau217 in amyloid-positive people, with the steepest increase in those who also have tangles.